Welcome to our dedicated page for TuHURA Biosciences SEC filings (Ticker: HURA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The TuHURA Biosciences, Inc. (NASDAQ: HURA) SEC filings page provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. TuHURA is a Phase 3 immuno-oncology company developing IFx-2.0, a lead innate immune agonist for advanced or metastatic Merkel cell carcinoma, the VISTA inhibiting monoclonal antibody TBS-2025 for NPM1-mutated relapsed/refractory acute myeloid leukemia, and Delta Opioid Receptor-based antibody drug conjugate programs aimed at overcoming resistance to cancer immunotherapy.
Through this page, users can review TuHURA’s current and historical filings, including Form 10-K annual reports, Form 10-Q quarterly reports, and Form 8-K current reports that disclose material events. Recent 8-K filings describe, among other items, the completion of the acquisition of Kineta, Inc., the reverse merger with Kintara Therapeutics, Inc., the initiation of the Phase 3 IFx-2.0 trial under a Special Protocol Assessment agreement with the FDA, the establishment of an at-the-market offering facility, a secured bridge loan agreement, and the effectiveness of a shelf registration statement on Form S-3.
Investors can also use this page to locate registration statements such as Form S-1 and Form S-3 related to public and resale offerings of TuHURA’s common stock, including PIPE financings and warrant exercises. Where applicable, pro forma financial information filed as exhibits to 8-Ks provides combined financial data reflecting TuHURA’s merger transactions. Insider ownership changes and executive equity activity, when reported on Form 4 and related forms, can be monitored alongside these core filings.
Stock Titan enhances this raw filing data with AI-powered summaries that highlight key points from lengthy documents, helping users understand how TuHURA’s clinical development plans, risk factor updates, financing arrangements, and merger-related disclosures appear in its official SEC reports. Real-time updates from EDGAR ensure that new TuHURA filings, including 10-Ks, 10-Qs, 8-Ks, registration statements, and ownership reports, are quickly available for review and comparison.
TuHURA Biosciences, Inc. entered into a Loan Agreement with Parkview Holdings One LLC, an affiliate of its largest stockholder, establishing a $50 million revolving credit facility maturing on April 21, 2031. The facility bears 12% annual interest, rising by an additional 6% during events of default, and is secured by substantially all assets of the company and its subsidiaries.
TuHURA may draw once per month, up to the greater of $1.7 million or the agreed budgeted monthly expenses, with unused capacity rolling forward. Subject to stockholder approval of related share issuances, the company expects this facility to fund operations and development programs into the first quarter of 2028. In connection with the loan, Parkview receives a low to mid‑single digit royalty on annual Net Sales of IFx‑2.0‑based products up to $450 million per year, and the agreement imposes customary covenants and change‑of‑control conversion rights.
TuHURA Biosciences filed a prospectus supplement to sell up to $50,000,000 of its common stock through an at-the-market (ATM) offering under a Sales Agreement with H.C. Wainwright & Co., LLC. The Sales Agent will receive a 3.0% commission on gross sales. The company states proceeds are intended for working capital and general corporate purposes. The prospectus uses an assumed price of $1.79 per share (last reported sale on March 31, 2026) for illustrative dilution calculations and reports 59,336,104 shares outstanding as of December 31, 2025.
TuHURA Biosciences, Inc. reported 2025 executive compensation decisions and released detailed pro forma results reflecting its acquisition of Kineta, Inc. and a June 2025 private placement. The compensation committee approved 2025 performance bonuses of $490,536 for CEO Dr. James Bianco and $163,393 for CFO Dan Dearborn, along with 5% cost-of-living raises, bringing their annual base salaries to $605,956 and $403,676, respectively.
The unaudited pro forma condensed combined statement of operations for the year ended December 31, 2025 shows a pro forma net loss attributable to common stockholders of $34,571,619, or $0.64 per share, based on 54,277,032 weighted-average shares. It incorporates TuHURA’s acquisition of Kineta, which was valued at total consideration of $16,560,163 and treated TuHURA as the accounting acquirer, and includes a June 2025 private placement of 4,759,309 shares at a combined $2.65 per share and accompanying warrant, with matching warrants exercisable at $3.3125 per share.
TuHURA Biosciences reported fourth quarter and full year 2025 results and highlighted progress across its immuno-oncology pipeline. The company is running a Phase 3 accelerated approval trial of IFx-2.0 in advanced or metastatic Merkel Cell Carcinoma and a Phase 1b/2a study in MCC of unknown primary, while advancing VISTA inhibitor TBS-2025 and an ADC program toward key 2026–2027 milestones.
Cash and cash equivalents were $3.6 million at December 31, 2025, with an additional $7.5 million received in Q1 2026 from a 2025 registered direct offering. Research and development expenses rose to $20.5 million in 2025 from $13.3 million in 2024, and general and administrative expenses increased to $7.6 million from $3.9 million, reflecting expanded operations and the Kineta acquisition. Net cash outflows from operating activities were $27.7 million in 2025, partly offset by $19.9 million of net cash inflows from financing activities. TuHURA reported approximately 52.9 million shares outstanding as of December 31, 2025.
TuHURA Biosciences, Inc. files its annual report describing a late‑stage immuno‑oncology pipeline focused on overcoming primary and acquired resistance to cancer immunotherapies. The company is a Phase 3 clinical-stage developer centered on its IFx innate immune agonist platform.
Lead candidate IFx‑2.0 is in a single randomized, placebo‑controlled Phase 3 trial as adjunctive therapy to Keytruda in first‑line advanced or metastatic Merkel cell carcinoma under an FDA Special Protocol Assessment and accelerated approval pathway. TuHURA also acquired Kineta and its VISTA‑inhibiting antibody TBS‑2025 for planned Phase 1b/2 studies in relapsed/refractory mutNPM1 acute myeloid leukemia, and is advancing Delta Opioid Receptor–targeted bi‑functional, bi‑specific ADCs against myeloid‑derived suppressor cells.
The report outlines the company’s history of reverse mergers, licensing deals with Moffitt Cancer Center and West Virginia University for DOR technology, a broad patent estate extending into the 2040s, and an organization of 22 employees based primarily in Tampa, Florida.
Tendler Craig reported acquisition or exercise transactions in a Form 4 filing for HURA. The filing lists transactions totaling 156,240 shares. Following the reported transactions, holdings were 156,240 shares.
Ng George K reported acquisition or exercise transactions in a Form 4 filing for HURA. The filing lists transactions totaling 156,240 shares. Following the reported transactions, holdings were 156,240 shares.
TuHURA Biosciences, Inc. reported that Highbridge Capital Management, LLC has become a significant holder of its common stock through warrants. Highbridge reports beneficial ownership of 6,060,608 shares of TuHURA common stock, all issuable upon exercise of warrants held by funds and accounts it advises.
This position represents 9.1% of TuHURA’s common stock, calculated using 60,720,508 shares outstanding as of December 10, 2025, after a recently completed offering and assuming warrant exercise. Highbridge has sole voting and dispositive power over these warrant shares and is filing as an investment adviser.
The filing states the securities were acquired and are held in the ordinary course of business, not with the purpose or effect of changing or influencing control of TuHURA. Highbridge Tactical Credit Master Fund, L.P., one of the advised funds, has rights over more than 5% of the outstanding shares.
MANUSO JAMES S J reported acquisition or exercise transactions in a Form 4 filing for HURA. The filing lists transactions totaling 156,240 shares. Following the reported transactions, holdings were 156,240 shares.
List Alan reported acquisition or exercise transactions in a Form 4 filing for HURA. The filing lists transactions totaling 156,240 shares. Following the reported transactions, holdings were 156,240 shares.